G. Aras

OBSERVE-5 interim analysis: an observational postmarketing safety registry of etanercept for the treatment of psoriasis.

A. Kimball, A. Menter, J. Gelfand, 2013, Journal of the American Academy of Dermatology.

Design and rationale of the Study of Etanercept and Methotrexate in Combination or as Monotherapy in Subjects with Psoriatic Arthritis (SEAM-PsA)

L. Coates, D. Gladman, P. Mease, 2018, RMD Open.

Defining and characterizing sustained remission in patients with rheumatoid arthritis

P. Emery, D. Collier, B. Haraoui, 2017, Clinical Rheumatology.

Pharmacokinetics, Immunogenicity, and Efficacy of Etanercept in Pediatric Patients With Moderate to Severe Plaque Psoriasis

A. Paller, T. Yuraszeck, J. Gibbs, 2018, Journal of clinical pharmacology.

Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis.

J. Ortonne, A. Menter, K. Papp, 2012, The New England journal of medicine.

Persistence of tumor necrosis factor inhibitor or conventional synthetic disease-modifying antirheumatic drug monotherapy or combination therapy in psoriatic arthritis in a real-world setting

J. Greenberg, P. Mease, D. Collier, 2019, Rheumatology International.

OBSERVE-5: observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results.

A. Kimball, K. Rothman, A. Menter, 2015, Journal of the American Academy of Dermatology.

Decreased Injection Site Pain Associated with Phosphate-Free Etanercept Formulation in Rheumatoid Arthritis or Psoriatic Arthritis Patients: A Randomized Controlled Trial

G. Kricorian, B. Stolshek, G. Aras, 2019, Rheumatology and Therapy.